Drug developer Immuron’s Travelan anti-diarrhoea oral antibody product set the company share price alight this morning following positive news from clinical trials in the United States. Travelan, which is made in Melbourne and on sale through Chemist Warehouse, is a non-absorbable, safe product which is composed of anti-bacterial antibodies that boost the gut immune system.…
A second new drug from biotechnology company Immuron is to undergo human trials in the United States following a decision by the Food and Drug Administration that allows trials to proceed. The Melbourne company told investors the US Naval Medical Research Centre (NMRC) had received approval to trial the drug targeting Campylobacter and Enterotoxigenic Escherichia…
ASX and NASDAQ-listed biotechnology company Immuron has deprioritised its SARS-Cov-2 R&D to focus on clinical development of more advanced-stage therapeutic drug candidates, it announced on Friday.
Immuron’s Travelan anti-diarrhoea product has moved to the human clinical trial phase in a program led by the Uniformed Services University in the United States. Travelan, which is made in Melbourne and on sale through Chemist Warehouse, is a non-absorbable, safe product which is composed of anti-bacterial antibodies that work on the gut immune system.…
Biotechnology company Immuron has announced positive results for its anti-diarrhoea vaccine in targeting the main bacteria responsible for sickness that besets international travellers and personnel stationed overseas such as the military. The United States Naval Research Centre (NMRC) has completed analysis of cows vaccinated against Campylobacter and Entereotoxigenic Escherichia coli, noting a ‘robust immune response’.…
Hot on the heels of reporting anti-Covid-19 action by one of the drugs it is developing, biotechnology company Immuron has raised $28 million (US$20 million) from institutional investors. On Tuesday the company reported its Travelan product for the prevention of travellers’ diarrhoea demonstrated neutralising activity against severe acute respiratory syndrome coronovirus-2, the virus that causes…
The US Defence Department is to lodge an investigational new drug (IND) application with the Food and Drug Administration to press on with studies of Immuron’s novel treatment of gut pathogens. The DoD Naval Medical Research Centre (NMRC) has requested a meeting with the FDA for guidance on Phase 2 trials of the Melbourne drug…
Listed gut health company Immuron (ASX: IMC) has received a $5.5 million grant from the US Department of Defence to develop a new oral drug targeting bacteria that cause ill health. The company, which markets Travelan for the prevention of travellers’ diarrhoea, will develop a combination anti-microbial preventative medicine for clinical evaluation. The product will…
Rio Tinto spends up big with local suppliers Rio Tinto increased its spend with suppliers and local businesses in Australia to more than $16.1 billion in 2023, as part of the company’s commitment to support communities where it operates. This was an increase of five per cent on the previous year and was spent with…
WA offers new Defence Ready Initiative grants The Western Australian government has opened applications for the latest round of Defence Ready Initiative grants to support local businesses in the defence sector. The purpose of the $200,000 investment is to assist small and medium enterprises enhance their capability, capacity and competitiveness to enter or expand their…
